Drug Trial Radar · NCT02198378
Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia.
Last checked: Nov 19, 2026Latest source record: Feb 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
680
Actual
Start
Nov 2014
Primary completion
Jan 2017
Study completion Jan 2017
Sponsor
- Lead sponsor
- University Hospital, ToulouseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the management of acute coronary syndromes with ST-segment elevation (STEMI), early analgesia reduces the effects of hyperadrenalism which increases the size of myocardial infarction. In order to reduce pain intensity, the recommendations advocate emergency use of morphine. In STEMI patients, other analgesic treatments could provide analgesia that is at least as effective as morphine. The equimolar oxygen/nitrous oxide mixture (MEOPA) is widely used in emergency medicine and has minor secondary effects that are very rapidly reversible when inhalation is discontinued. Used in association with paracetamol, it could be an at least equally effective alternative to the use of morphine.
Conditions
- Acute Coronary Syndrome
Interventions
MEOPA and paracetamolDrug
The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
MorphineDrug
Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN\> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effective analgesia (NRS score≤ 3) at 30 minutes after the start of analgesiaTime frame: 30 minutes after randomisation.
Locations
40 sites in 2 countries. Site status is shown where the registry gives one.
Centre Hospitalier d'Agen
Agen, France
Centre Hospitalier Jean Minjoz
Besançon, France
CHU Avicenne
Bobigny, France
Hôpital Pellegrin
Bordeaux, France
Centre Hospitalier Bourg-en-Bresse
Bourg-en-Bresse, France
Centre Hospitalier de Chambéry
Chambéry, France
Centre Hospitalier Louis Pasteur
Chartres, France
Centre Hospitalier Chateauroux
Châteauroux, France
CHU d'Estaing
Clermont-Ferrand, France
Centre Hospitalier Beaujon
Clichy, France
Centre Hospitalier Alpes Léman
Contamine-sur-Arve, France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France
Centre Hospitalier Dijon
Dijon, France
Centre Hospitalier du Val d'Ariège
Foix, France
Centre Hospitalier Raymond Poincaré
Garches, France
Centre Hospitalier de Grenoble
Grenoble, France
Centre Hospitalier Départemental La Roche/Yon
La Roche-sur-Yon, France
CHRU Lille
Lille, France
CHU Dupuytren
Limoges, France
Centre Hospitalier Edouard Herriot
Lyon, France
Centre Hospitalier de la Timone
Marseille, France
Centre Hospitalier Marc Jacquet
Melun, France
CHR Bon Secours
Metz, France
CHRU Montpellier
Montpellier, France
CHU Nancy
Nancy, France
CHU Nantes
Nantes, France
Centre Hospitalier de Nice
Nice, France
Centre Hospitalier Necker
Paris, France
Centre Hospitalier Pitié-Salpétrière
Paris, France
Groupe hospitamier Lariboisière-Fernand Widal-St-Louis
Paris, France
CHU Poitiers
Poitiers, France
Centre Hospitalier René Dubos
Pontoise, France
Centre Hospitalier Annecy-Gennevois
Pringy, France
Centre Hospitalier Comminges Pyrénées
Saint-Gaudens, France
Centre Hospitalier Poulon la Seyne-sur-mer
Toulon, France
CHU Toulouse
Toulouse, France
CHRU Tours
Tours, France
Centre Hospitalier de Valence
Valence, France
Centre Hospitalier Lucien Hussel
Vienne, France
CHU Félix Guyon
Saint-Denis, Reunion
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.